Nouriast (パーキンソン病)：医薬品市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 14
3.1.3 Prognosis 16
3.1.4 Quality of Life 17
3.2 Symptoms 17
4 Disease Management 19
4.1 Overview 19
4.1.1 Diagnosis – The UK Brain Bank Criteria 19
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.2 Treatment Synopsis 23
4.2.1 Dopaminergic Therapy Classes 23
4.2.2 Treatment of Parkinson’s Disease by Stage 25
4.2.3 Other Treatment Options 28
4.3 Parkinson’s Disease Assessment Scales 28
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 29
4.3.2 Hoehn and Yahr Clinical Staging 31
4.3.3 Other Clinical Assessments 32
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 35
5.3 Product Profiles – Adenosine 2A Inhibitor 37
6 Nouriast (istradefylline) 38
6.1 Overview 38
6.2 Efficacy 39
6.3 Safety 40
6.4 SWOT Analysis 40
6.5 Forecast 41
7 Appendix 42
7.1 Bibliography 42
7.2 Abbreviations 46
7.3 Methodology 49
7.4 Forecasting Methodology 49
7.4.1 Diagnosed Parkinson’s Disease Patients 49
7.4.2 Percent Drug-Treated Patients 50
7.4.3 General Pricing Assumptions 50
7.4.4 Compliance Assumptions 51
7.4.5 Individual Drug Assumptions 52
7.4.6 Generic Erosion 52
7.5 Physicians and Specialists Included in this Study 53
7.6 About the Authors 55
7.6.1 Author 55
7.6.2 Global Head of Healthcare 56
7.7 About GlobalData 57
7.8 Disclaimer 57